Allorion Therapeutics

Allorion Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 by Qiang Ding and Fang Li, developing novel small-molecule therapies for cancer and autoimmune disease. Operating from Natick, Massachusetts and Guangzhou, China, Allorion applies mutant-selective and isoform-specific medicinal chemistry across a pipeline that includes ARTS-011 (a TYK2 inhibitor), ARTS-021 (a CDK2 inhibitor targeting CCNE1-amplified tumors), and ARTS-023/AVZO-023 partnered with Avenzo Therapeutics, alongside an exclusive option and global license agreement with AstraZeneca for an allosteric EGFR L858R inhibitor. The company is a drug-discovery organization backed by Qiming Venture Partners and INCE Capital; it markets internal data and high-throughput screening platforms but publishes no public developer program, API, SDK, or machine-readable specification.

Allorion Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Oncology.

Allorion Therapeutics’ developer surface includes product news and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsDrug DiscoveryOncologyAutoimmuneLife SciencesClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 6.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/allorion-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

About

News

Careers

LinkedIn

Twitter

Twitter

Other 4

Properties that don't map to a standard resource type

Team

Pipeline

Presentations

SecondaryMarket

Source (apis.yml)

aid: allorion-therapeutics
name: Allorion Therapeutics
image: https://alloriontx.com/wp-content/uploads/2024/02/Allorion_Logo_web.png
description: Allorion Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 by Qiang Ding and Fang Li,
  developing novel small-molecule therapies for cancer and autoimmune disease. Operating from Natick, Massachusetts and Guangzhou,
  China, Allorion applies mutant-selective and isoform-specific medicinal chemistry across a pipeline that includes ARTS-011
  (a TYK2 inhibitor), ARTS-021 (a CDK2 inhibitor targeting CCNE1-amplified tumors), and ARTS-023/AVZO-023 partnered with Avenzo
  Therapeutics, alongside an exclusive option and global license agreement with AstraZeneca for an allosteric EGFR L858R inhibitor.
  The company is a drug-discovery organization backed by Qiming Venture Partners and INCE Capital; it markets internal data
  and high-throughput screening platforms but publishes no public developer program, API, SDK, or machine-readable specification.
url: https://raw.githubusercontent.com/api-evangelist/allorion-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Oncology
- Autoimmune
- Life Sciences
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/allorion-therapeutics-domain-security.yml
- type: WellKnown
  url: well-known/allorion-therapeutics-well-known.yml
- type: LLMsTxt
  url: llms/allorion-therapeutics-llms.txt
- type: Website
  url: https://alloriontx.com/
- type: About
  url: https://alloriontx.com/overview/
- type: Team
  url: https://alloriontx.com/our-team/
- type: Pipeline
  url: https://alloriontx.com/pipeline/
- type: Presentations
  url: https://alloriontx.com/presentations/
- type: News
  url: https://alloriontx.com/news/
- type: Careers
  url: https://alloriontx.com/careers/
- type: Contact
  url: https://alloriontx.com/contact/
- type: LinkedIn
  url: https://www.linkedin.com/company/alloriontx/
- type: Twitter
  url: https://twitter.com/AllorionT
- type: SecondaryMarket
  url: https://www.nasdaqprivatemarket.com/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Allorion Therapeutics is a clinical-stage small-molecule drug-discovery company whose only web surface is an eight-page
    WordPress corporate site (Overview, Team, Pipeline, Presentations, News, Careers, Contact) — no api., developer., docs.,
    dev., portal. or app. host resolves for alloriontx.com, no allorion/alloriontx/allorion-therapeutics GitHub organisation
    exists, and /openapi.json, /swagger.json, /graphql, /.well-known/agent-card.json, /.well-known/agent.json, /.well-known/security.txt
    and /.well-known/api-catalog all resolve to the site's WordPress 404 page behind a SiteGround CAPTCHA interstitial that
    answers every automated request with HTTP 202.
  evidence:
  - url: https://alloriontx.com/openapi.json
    status: 404
  - url: https://alloriontx.com/.well-known/agent-card.json
    status: 404
  - url: https://alloriontx.com/.well-known/agent.json
    status: 404
  - url: https://alloriontx.com/graphql
    status: 404
  - url: https://api.github.com/orgs/alloriontx
    status: 404
  checked: '2026-08-06'